DIA conducted a study in collaboration with the Tufts Center for the Study of Drug Development (CSDD) and found that 65 percent of pharmaceutical and biotech companies surveyed are investing in patient-centric initiatives in drug development.
Reported benefits include: reduced screen failure rates, faster patient recruitment, improved subject retention, reduced protocol amendments, and a greater number of patient relevant endpoints. In the study, cost to conduct, ease of conducting, and reported impact were measured.
Tools and resources included in the DIA Patient Engagement Study Findings:
Lorem ipsum dolor sit amet consectetur adipisicing elit. Quam laborum reprehenderit amet in rerum id eum harum qui quos. A est consequatur reprehenderit necessitatibus repudiandae quia harum dolorum praesentium temporibus?
Lorem ipsum dolor sit amet consectetur adipisicing elit. Libero pariatur, illum iure sapiente eveniet, eos eligendi numquam aliquam, asperiores ea sit tempora praesentium aliquid dolore cumque animi omnis autem voluptas!
Lorem ipsum dolor sit amet consectetur adipisicing elit. Consectetur, similique enim? Deserunt, quos eos! Vel aut magnam officia labore quo, laborum deserunt veritatis iste, molestias, illum alias voluptate debitis perspiciatis?
